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Edited by Daniela RuﬀellAbstract Anti-apoptotic proteins are involved in modulating the
process of apoptosis. Here, we report the identiﬁcation of the
previously uncharacterized transmembrane domain protein 85
(TMEM85) as a novel anti-apoptotic sequence. Using growth
and viability assays, we demonstrate that the heterologous
expression of human TMEM85 in yeast promotes growth and
prevents cell death in response to oxidative stress. Overexpres-
sion of the yeast TMEM85 ortholog (YGL231c) also leads to in-
creased resistance to oxidative stress. Analysis of the existing
TMEM85 DNA complimentary to mRNAs revealed that the hu-
man TMEM85 gene is alternatively spliced to produce multiple
transcripts and proteins. Thus TMEM85 is a complex gene that
encodes a novel conserved anti-apoptotic protein.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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apoptosis1. Introduction
Extensive studies of the past few years demonstrate thatSac-
charomyces cerevisiae undergoes a form of intrinsic apoptosis
comparable to that seen in metazoans [1]. Apoptotic yeast cells
show typical hallmarks of metazoan apoptosis including chro-
matin condensation, DNA degradation, and externalization of
phosphatidylserine. Other hallmarks of mammalian apoptosis
are also seen in yeast under conditions of stress: cytochrome c
is released from the mitochondria, the AIF1 homologue Aif1p
is also released from the mitochondria, and yeast present with
the characteristic apoptotic morphology [2–5].
Yeast has long been used as a model in which to functionally
express human genes for a number of diﬀerent applications
including functional analysis [6]. Among the results of such
investigations were the discoveries that mammalian pro-apop-Abbreviations: aa, amino acid(s); cDNA, DNA complimentary to
mRNA; DTT, dithiothreitol; H2O2, hydrogen peroxide; RT-PCR,
reverse transcriptase-polymerase chain reaction; TMEM85, transmem-
brane domain protein 85; YNB, yeast nitrogen base
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doi:10.1016/j.febslet.2008.06.042totic proteins such as Bax, caspases, and the Apaf-1 homo-
logue, CED4, induced apoptosis in yeast [7–10]. General
protection to multiple stresses including those leading to apop-
tosis is conferred on yeast cells by prior exposure to mild stres-
ses such as heat shock and the overexpression of anti-apoptotic
sequences such as genes encoding for anti-oxidant proteins
[11,12]. Utilizing heterologous expression of Bax a variety of
proteins including BI-1 and prion protein were identiﬁed as
anti-apoptotic in yeast [6,10,13,14]. To further understand the
molecular basis of anti-apoptosis we sought to identify novel
anti-apoptotic sequences by screening mammalian DNA com-
plimentary to mRNA (cDNA) expression libraries in yeast
which conditionally express the mouse pro-apoptotic Bax
[15–17]. We thus reported that cDNAs encoding mammalian
VPS24, SMS1 and TSC-22 serve to increase viability in re-
sponse to diﬀerent stresses and are likely functional anti-apop-
totic sequences in yeast. Here we report the characterization of
a cDNA encoded by the human transmembrane domain pro-
tein 85 (TMEM85) gene as a novel suppressor of Bax and
hydrogen peroxide (H2O2) mediated cell death in yeast.2. Materials and methods
2.1. Plasmids
The TMEM85v2 clone, expressed under the control of the GAL1
promoter in pYES-DEST52, was isolated in our previous screen for
Bax suppressors [17]. Plasmid BG1805-YGL231c contains a URA3
selectable marker and the entire open reading frame of YGL231c under
the control of the GAL1 promoter (Open Biosystems).
2.2. Yeast strains and growth
The S. cerevisiae BY4741strain (MATa his3D1 leu2D0 met15D0
ura3D0) and the isogenic strain lacking the YGL231c gene were used
(EUROSCARF). Strains having a TAP tag in the endogenous
YGL231c or YBL075c (SSA3) genes were from Open Biosystems.
Yeast were grown in synthetic minimal media containing yeast nitro-
gen base (YNB), 2% glucose and supplemented with the required ami-
no acids (aa) or bases. When expression of the GAL1 promoter was
required, the glucose was substituted with 2% galactose and 2% raﬃ-
nose. Yeast cells were transformed with the appropriate plasmids using
the lithium acetate method. The rich media used consisted of 2%
bactopeptone, 1% yeast extract and 2% glucose (YEPD).2.3. Viability and growth assays
A colony forming unit (CFU) assay was used to assess cell viability
[17]. Transformed yeast were grown overnight in minimal media
containing glucose, diluted into fresh minimal media containing galact-
ose and grown for 2 h (1–2 · 106 cells/ml) and treated with diﬀerentblished by Elsevier B.V. All rights reserved.
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tunicamycin) for 4 h. Triplicate samples of 200 cells were then plated
on YEPD media, grown at 30 C and the number of colonies that
formed after 2 days were counted. For UV treatment, two hundred
yeast cells were plated on YEPD nutrient agar then exposed to
350 · 100 lJ/cm2 UV. The spot growth and the H2O2 halo assays using
a lawn of yeast cells growing and a H2O2 spotted ﬁlter disk are de-
scribed [11,17]. At least three independent experiments were performed
for all these assays.
2.4. RT-PCR
RNA isolation and reverse transcriptase-polymerase chain reaction
(RT-PCR) was carried out as described [18]. The TMEM85 speciﬁc
transcripts were ampliﬁed using equal aliquots of reverse transcribed
RNA under the following conditions: 94 C for 30 s, 57 C for 30 s,
72 C for 40 s, for a total of 35 cycles. The forward primers used were
5 0-GAAGCATCGAGGCTATAGGAC-3 0 for TMEM85v1, v2, and
v3, and 5 0-CTGGAAAACCTATAGGGAA-3 0 for TMEM85v4. The
reverse primers used were 5 0-AATGAAGGGTAACCAATCCGA-30
for TMEM85v1 and v3, 5 0-CAGTCCTCCACCACTGAACTC-30
for TMEM85v2, and 5 0-GCAGGCAGATCGCTTGAGCCC-30 for
TMEM85v4. b-ACTIN mRNA was ampliﬁed using the forward:
5 0-GTGGGCCGCCCTAGGCACCAG-30 and reverse: 5 0-CTCTT-
TGATGTCACGCACGATTTC-3 0 primers [18].3. Results and discussion
We have previously isolated multiple mammalian cDNAs
capable of suppressing the Bax mediated growth and or viabil-
ity defects in yeast [17]. Here, we report the characterization of
a cDNA encoding a 149 aa protein corresponding to the
uncharacterized transmembrane spanning protein 85
(TMEM85, also called proliferation-inducing gene 17). We
have named the clone isolated here TMEM85v2 since it repre-
sents a splice variant of the human TMEM85 gene (see Section
3.2).
3.1. TMEM85v2 protects against Reactive Oxygen species
induced stress
In addition to inducing apoptosis, Bax expression in yeast
may also have other eﬀects such as the inhibition of cell growth
[10,19]. To determine if TMEM85v2 is anti-apoptotic, we
therefore examined whether it could prevent cell death in re-
sponse to H2O2 treatment that induces apoptotic like death
[20]. In the absence of H2O2, viability for yeast transformed
with empty vector or with plasmids expressing a known anti-
apoptotic sequence (BS.22) [17], or a TMEM85v2 was close
to 100% (Fig. 1A). After treatment, the respective viability of
control cells, BS.22 and TMEM85v2 expressing cells was de-
creased to 22.2 ± 5%, 58 ± 3.5% and 60.2 ± 0.4% (Fig. 1A).
This indicates that TMEM85v2 was able to protect cells from
ROS induced cell death. We also examined the ability of
TMEM85v2 to protect cells from other apoptotic inducing-
stresses. Viability was decreased in control cells exposed to
UV, DTT or tunicamycin to a respective 38.9 ± 11%,
19.8 ± 1.4% and 19.6 ± 4.1% (Fig. 1B–D). In contrast to what
was observed with H2O2 we found no signiﬁcant protective ef-
fect with either BS.22 or TMEM85v2 (Fig. 1B–D). These re-
sults are consistent with the notion that diﬀerent genes are
required to protect cells against diﬀerent stresses [21].
A halo assay was performed to conﬁrm the ability of
TMEM85v2 to protect yeast cells from H2O2. In this assay,
cells are plated on nutrient agar media and a ﬁlter disk con-
taining H2O2 is placed on the media [11]. The size of the zone
of no growth around the disk is indicative of the sensitivity tothe stress. On glucose media, the halo sizes for cells harbouring
the empty or the TMEM85v2 vector are the same. On galact-
ose media, cells grow slower and the halo for control cells is
consequently larger. In contrast, the halo surrounding the cells
expressing TMEM85v2 is smaller which indicates that can pro-
tect yeast (Fig. 1E). Taken together these results suggest that
TMEM85v2 represents a novel anti-apoptotic sequence.
3.2. Genomic organization and alternative splicing of human
TMEM85
Fifteen diﬀerent human TMEM85 cDNA sequences exist in
GenBank. Twelve of these code for a 183 aa protein (i.e.
GenBank CR599971). Our TMEM85v2 cDNA encodes a
149 residue protein that has an identical N-terminus but a dif-
ferent C-terminal sequence. Given that the DNA sequences at
the 5ends of both clones are identical, alternative splicing is
likely responsible for the observed diversity. We used BLAST
to compare the sequences of the diﬀerent TMEM85 cDNAs
with the human genomic sequence. We found a single
TMEM85 gene that is spread over 5.1 kb on human chromo-
some XV (GenBank AC079203). It consists of ﬁve exons that
are alternatively spliced to produce at least four diﬀerent
mRNA variants (v) that we have named TMEM85v1,
TMEM85v2, TMEM85v3, and TMEM85v4 (Fig. 2). While
exons 1, 2, 3B and 5 all follow the GT/AG splicing rule-they
are likely spliced by the U2 spliceosome, exon 3A appears to
follow the splicing determinants of the U12 spliceosome, AT/
variable 3 0 splice site (Supplementary Table 1).
Human TMEM85v1 consists of exons 1, 2, 3B, 4, and 5B
and its protein is predicted to contain two transmembrane
domains, a DUF1077 domain that represents a conserved do-
main of unknown function (Fig. 2A and B). The TMEM85v2
sequence isolated here, is represented once in the database
(GenBank BC002583) and corresponds to a transcript that is
composed of exons 1, 2, 3B, and 5B (Fig. 2). It is predicted
to produce a 149 aa protein that contains one transmembrane
domain and most of the DUF1077 domain. The absence of
exon 4 causes a translational frame shift in the coding region
of v2, giving rise to a unique C-terminal sequence.
In addition to these two variants, there are two other human
cDNAs present in the GenBank database that suggests addi-
tional complexity. TMEM85v3 (GenBank CR609616) contains
exons 1 and 5B only and is predicted to encode for a 87 aa sol-
uble protein with no recognizable functional domain (Fig. 2A
and B). TMEM85v4 (GenBank AK091678) is encoded by exon
3A and all of exon 5 (Fig. 2A and B). Although the GenBank
entry does not predict a protein sequence, ORF Finder, sug-
gests that it encodes a 66 aa protein that contains a short re-
gion of the DUF1077 domain (Fig. 2B).
Semi-quantitative RT-PCR was performed using primers
which allowed identiﬁcation of the individual TMEM85 tran-
scripts in both human and mouse (Fig. 2A). TMEM85v1, v2,
and v3 were all identiﬁable in DNA from a human heart
cDNA library, TMEM85v1 and v3 were found in a human foe-
tal brain cDNA library and only TMEM85v1 could be de-
tected in the human kidney cell line HEK293. The putative
TMEM85v4 transcript was not identiﬁed in any of the human
samples tested (Fig. 2C). Using the RNA isolated from a panel
of mouse tissues and cell lines, TMEM85v1 and v4 were de-
tected in wide range of tissues while TMEM85v2 and v3 were
detected only in kidney and testis (Supplementary Fig. 1). Ta-
ken together, these results indicate that the mammalian
Fig. 1. Human TMEM85v2 suppresses the loss of viability and the growth inhibitory aﬀects of hydrogen peroxide. Yeast cells were transformed with
empty vector, positive control (BS. 32), or TMEM85v2 expressing vector and either left untreated (black bars) or treated (grey bars) with (A) H2O2,
(B) UV, (C) tunicamycin and (D) DTT. Viability was determined using the colony forming unit assay. Data is presented as the percentage (±standard
error) of treated cells that are plated that form colonies. An asterisks ‘‘*’’ indicates that the viability of BS. 32 and TMEM85v2 expressing cells is
signiﬁcantly diﬀerent than cells harbouring empty vector (Students t-test, P < 0.001). (E) Hydrogen peroxide halo assays were performed with yeast
cells harbouring either the empty vector or the TMEM85v2 expressing plasmid. The plates were incubated at 30 C for 2–3 days and a photograph of
the resultant plates is shown.
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spliced to produce multiple transcripts and proteins. Thus theTMEM85 gene is somewhat typical of many other genes in-
volved in apoptosis [15,16,18,22].
Fig. 2. Schematic representation of the human TMEM85 gene, the predicted topology of the proteins and tissue distribution of the mRNAs. (A)
Exons of the TMEM85 gene are shown as numbered coloured boxes while the introns are shown as lines. Arrows indicate the position of primers
(called a, b, c and d) used for RT-PCR analysis. Exon 3 consists of two joined exons, 3A and 3B, that contain an overlapping 132 bp region (shown in
green). The four transcripts are labelled as v1–v4. The colour scheme used to diﬀerentiate the diﬀerent exons was also used in the depiction of the
diﬀerent transcripts. The size of the diﬀerent proteins predicted to be produced from the diﬀerent transcripts is also shown. Colours are used to
denote the identity between the diﬀerent proteins while the transmembrane domains are indicated in pink. (B) Schematic representation of the
topology of the four putative TMEM85 proteins with respect to a lipid bilayer. Sequences shared between the diﬀerent proteins are indicated by the
use of the same colour. (C) RT-PCR analysis of the TMEM85 transcripts in human tissues and cell lines and cDNA libraries. An aliquot of each
PCR reaction was separated on 1.5% agarose gels, stained with ethidium bromide, visualized and a composite of the resultant photographs are
shown. The size in base pairs (bp) of each PCR product corresponding to the predicted size of the diﬀerent TMEM85 transcripts is shown on the
right. Similar results were obtained in two separate experiments.
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Although TMEM85 like proteins have been identiﬁed in as
many as 72 diﬀerent eukaryotic species (BLink, NCBI) its func-
tion remains elusive. S. cerevisiae also contains a TMEM85
orthologue encoded by YGL231c (GenBank NP_011283).
There is 26% sequence identity between the TMEMv1 and
YGL231c encoded proteins and 20% identity with TMEM v2
(Fig. 3A). YGL231c encodes an uncharacterized ORF of un-
known function that localizes to the endoplasmic reticulum
(http://www.yeastgenome.org/). Strains deleted for YGL231c
are viable and do not have any overt defects. To analyze a po-
tential anti-apoptotic role of YGL231c, we made use of theobservation that a decrease in the expression of many anti-
apoptotic genes often leads to an increase in the sensitivity to
apoptotic stimuli [23]. We therefore determined the viability
of both the wild type and the isogenic yeast deletion mutant
YGL231cD, after treatment with diﬀerent apoptotic inducing
stimuli. Viability of wild type cells decreased to a respective
41, 8 and 16% with H2O2, DTT or tunicamycin (Fig. 3B). There
was no statistically signiﬁcant diﬀerence in the viability of the
mutant lacking YGL231c when compared to wild type yeast
cells for all three stresses examined (Fig. 3B). The analysis of
the complete set of viable gene deletion strains from yeast has
lead to the identiﬁcation of several hundred genes that are re-
Fig. 3. Analysis of the sequence and of the overexpression of YGL231c, the yeast orthologue of the human TMEM85 gene. (A) Comparison of the
amino acid sequence of human TMEM85v1 and TMEM85v2 with yeast YGL231c. Regions of identity between all three sequences are shown in
blue, between TMEM85v2 and YGL231c are shown in red, between TMEM85v2 and YGL231c are shown in green. Gaps () are introduced to
maximize the alignment. (B) Deletion mutant yeast (YGL231cD) and wild type yeast were treated with 4 mM H2O2, 35 mM DTT, or 0.01 lg/ml
tunicamycin. Viability was compared between yeast exposed and not exposed to the stresses, and expressed as the percentage of cells plated that
formed colonies. Data are ± the standard error and represent a minimum of three independent experiments. (C) Halo assays were performed with
wild type yeast transformed with empty vector or with vector expressing YGL231c under the control of a galactose inducible promoter. The central
disc contained 2 ll of 30% hydrogen peroxide.
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H2O2 [21]. Our results are consistent with this study since
YGL231c was not identiﬁed in the screen.
Using the halo assay, the zone of no growth surrounding the
hydrogen peroxide containing ﬁlter is signiﬁcantly reduced in
galactose grown cells overexpressing YGL231c when compared
to control cells (Fig. 3C). Given that the increased resistance
was galactose dependant, we reasoned that the eﬀect was due
to the increased expression of YGL231c. Using the CFU assay,
the viability of galactose grown yeast cells following exposure
to H2O2 was 64 ± 6% for cells overexpressing YGL231c com-
pared to 38.2 ± 4% for cells having an empty vector. This sug-
gests that YGL231c like human TMEM85v2, is capable of
preventing cell death in response to pro-apoptotic stimuli
and therefore it is by deﬁnition an anti-apoptotic gene [24].
A screen of the complete set of viable gene deletion strains
from yeast that are more sensitive to the heterologous expres-
sion of a-synuclein has identiﬁed 86 diﬀerent genes including
YGL231c [25]. We found that there was a noticeable decrease
in the viability of YGL231cD cells expressing a-synuclein when
compared to wild type cells (40.1 ± 2.2% vs. 47.4 ± 1.8%). On
the other hand, although the viability of a-synuclein expressing
cells was dramatically decreased, we found that co-expression
of TMEM85v2 does protect yeast cells (Supplementary Fig. 2).
Given that we used a high copy number plasmid to express a-
synuclein, we cannot rule out the possibility that more subtle
approaches may uncover inter-relationships between a-synuc-
lein and TMEM85v2.4. Conclusion
Although the mechanism(s) by which TMEM85 functions is
still unknown, this study provides strong clues and more
importantly, the resistance to stress brought upon the expres-
sion of TMEM85v2 and YGL231c in yeast, provides a facile
model system to begin a detailed structural and functional
analysis of this novel gene.
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